Researchers identify a promising drug for treating serious COVID-19 complication in children
Study shows rapid improvement in children with MIS-C treated with drug first developed for celiac disease.
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
World-renowned pediatric gastroenterologist, research scientist and entrepreneur Dr. Alessio Fasano is chief of Pediatric Gastroenterology and Nutrition at MassGeneral Hospital for Children (MGHfC). Dr. Fasano directs the Center for Celiac Research, specializing in the treatment of patients of all ages with gluten-related disorders, including celiac disease, wheat allergy and gluten sensitivity. He treats patients with acute and chronic diarrheal diseases, and treats infants and children who have difficult-to-treat gastrointestinal problems.
Dr. Fasano also directs the Mucosal Immunology and Biology Research Center and is associate chief for Basic, Clinical and Translational Research. Under his leadership, investigators are studying the molecular mechanisms of autoimmune disorders including celiac disease, and other-gluten-related disorders. He has been named visiting professor of pediatrics at Harvard Medical School. He authored the groundbreaking study in 2003 that established the rate of celiac disease at one in 133 Americans. Widely sought after by national and international media, Dr. Fasano has been featured in hundreds of interviews including outlets such as The New York Times, The Wall Street Journal; National Public Radio; CNN; Bloomberg News, and others.
Departments, Centers, & Programs:
Clinical Interests:
Treats:
Languages:
MassGeneral Hospital for Children: Pediatric Gastroenterology & Nutrition Program
55 Fruit St.
Yawkey Center for Outpatient Care
Suite 6B
Boston, MA 02114
Phone: 617-726-8705
Medical Education
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Fasano is director of the Mucosal Immunology and Biology Research Center at MassGeneral Hospital for Children. Dr. Fasano's research established that celiac disease affects approximately 1 percent of the U.S. population, a significantly higher number than previously believed, and helped define gluten sensitivity as a condition on the spectrum of gluten-related disorders. His research also uncovered the role that impairment of the tight junctions between intestinal enterocytes plays in the development of celiac disease.
During research designed to develop a cholera vaccine, Dr. Fasano uncovered a toxin, zonula occludens, which causes diarrhea by loosening the tight junctions and allowing intestinal permeability. Subsequently, he identified the protein zonulin, which controls this process. He has since established the role of zonulin in the pathogenesis of a number of autoimmune diseases, including celiac disease, type 1 diabetes, and certain cancers and diseases of the nervous system.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is the #1 Research Hospital in America and recognized in 14 specialties assessed by U.S. News & World Report.
Study shows rapid improvement in children with MIS-C treated with drug first developed for celiac disease.
Antibody levels were lower in unvaccinated, COVID-infected mothers at delivery and in their infants.
By implementing a long-term, prospective approach to the development of celiac disease, a collaborative group of researchers has identified substantial microbial changes in the intestines of at-risk infants before disease onset.
Researchers have determined that viral particles remaining in the gut long after an initial COVID-19 infection can travel into the bloodstream, instigating the condition called Multisystem Inflammatory Syndrome in Children (MIS-C).
Gastrointestinal motility disorders affect the how the body moves food through the gastrointestinal tract. Learn about common types of motility disorders and symptoms, as well as different types of motility testing.
The CDGEMM Study enrolls infants who have a parent or sibling diagnosed with CD. The risk of developing CD for these infants is increased by 8-25% over that of the general population. Enrolled children are followed from birth until they reach five years of age.